Novartis to in-license Molecular Partners’ new COVID-19 drug ensovibep
Category: #headlines |   By Pankaj Singh |   Date: 2022-01-11

Novartis to in-license Molecular Partners’ new COVID-19 drug ensovibep
  • Novartis has confirmed that it will in-license ensovibep from Molecular Partners to expedite its manufacturing and regulatory approvals globally.
  • Molecular Partners will receive a milestone payment of 150 million and a 22% royalty on ensovibep sales in commercial areas after the in-licensing.

Officials from Swiss drugmaker Novartis and Molecular Partners, a clinical-stage biotech firm developing a new class of custom-built protein drugs, reportedly said an experimental drug dubbed ensovibep to treat COVID-19 patients could be on the market in a matter of weeks.

For the uninitiated, ensovibep, a multi-specific Designed Ankyrin Repeat Protein (DARPin), has been engineered to obstruct the receptor-binding domains of the SARS-CoV-2 spike protein via powerful and cooperative binding, making it difficult for escape mutants.

Novartis will pay Molecular Partners 150 million Swiss francs (USD 162.92 million) to in-license ensovibep to accelerate its production ramp-up and gain approval for the medicine. The therapeutics firm had previously received a 60-million-franc (approx. USD 65 million) upfront payment, including equity.

The two firms decided after receiving promising top-line findings from a phase-two study for ensovibep (mp0420). The antiviral for coronavirus will now be researched and marketed by Novartis.

A study on acute COVID-19 ambulatory patients equating single intravenous dosages of ensovibep to placebo suggested that the DARPin antiviral therapeutic applicant met the endpoint of viral load reduction over eight days, the two businesses stated in a statement.

According to the partners, the two secondary endpoints also revealed a clinically relevant advantage compared to a placebo.

As per Molecular Partners' website, DARPins provide a unique method for treating coronavirus by utilizing a single molecule that can engross as many as three segments of the SARS-CoV-2 virus at the same time, neutralizing the virus through several processes.

Novartis will first seek permission from the US Food and Drug Administration (FDA), with which it is applying for a EUA (Emergency Use Authorization).

Source Credit-

https://www.theedgemarkets.com/article/novartis-license-covid19-treatment-ensovibep-molecular-partners

  • shareShare
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh     Twitter

Pankaj Singh

With a commendable experience of content creation under his belt, Pankaj Singh, a qualified Post Graduate in Management, boasts of having worked as a freelance writer and an insurance underwriter. Additionally, Pankaj has also enriched his qualification portfolio with Read more...

More News By Pankaj Singh

Oracle Prepared to Assist Canadian Banks with Open Banking Transition

Oracle Prepared to Assist Canadian Banks with Open Banking Transition

By Pankaj Singh

The American tech giant Oracle has reportedly expressed its readiness to assist Canadian banks with their open banking requirements, offering necessary tools as needed once the country decides to make this service available. Sonny Singh, the Execu...

Goldman Sachs explores sale options for its fintech unit GreenSky

Goldman Sachs explores sale options for its fintech unit GreenSky

By Pankaj Singh

GreenSky was bought by Goldman Sachs in 2021 for USD 2.24 billion stock deal. Goldman Sachs quotes GreenSky as ‘good business’. Goldman cites itself not best suited to lead the fintech in long run . In the recent turn of event...

Tesla ordered to pay ex-employee over $3.2 Mn in damages over racism case

Tesla ordered to pay ex-employee over $3.2 Mn in damages over racism case

By Pankaj Singh

Electric car manufacturer, Tesla, has reportedly been ordered by a federal jury to pay more than USD 3.2 million in damages to a former worker, following his win in a racial harassment suit. Owen Diaz, who worked as a lift operator at the firm’...